Zentalis Pharmaceuticals, Inc. $ZNTL Shares Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP raised its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 188.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 317,600 shares of the company’s stock after buying an additional 207,600 shares during the quarter. Seven Fleet Capital Management LP owned approximately 0.44% of Zentalis Pharmaceuticals worth $1,451,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. GSA Capital Partners LLP purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter worth $1,815,000. ADAR1 Capital Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $3,166,000. 5AM Venture Management LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at about $19,147,378,000. Anfield Capital Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 239.9% during the fourth quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock worth $328,000 after buying an additional 171,228 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Zentalis Pharmaceuticals by 182.6% during the first quarter. Dimensional Fund Advisors LP now owns 272,034 shares of the company’s stock worth $634,000 after buying an additional 175,771 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have commented on ZNTL. Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Wall Street Zen cut Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Finally, Mizuho initiated coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.75.

Zentalis Pharmaceuticals Trading Up 0.3%

Shares of ZNTL stock opened at $3.89 on Thursday. The company has a market cap of $278.80 million, a price-to-earnings ratio of -1.99 and a beta of 1.92. The stock has a 50 day simple moving average of $4.36 and a 200-day simple moving average of $3.71. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.21 and a 12-month high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current fiscal year.

Insider Transactions at Zentalis Pharmaceuticals

In related news, major shareholder Group Walters bought 4,335,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the completion of the acquisition, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This represents a 32.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.80% of the company’s stock.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.